UK leads on new regulatory framework for point-of-care medicine manufacturing

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced the establishment of a ground-breaking regulatory framework to simplify the manufacture of innovative medicines at the point of care. The UK’s Human Medicines and Clinical Trials legislation will be amended to enable this and brought to parliament later in 2023.